PubMed · 2007 · 13 citations · 11 references
MedicineHematologyInternal MedicineCancer EpidemiologyHematologic OncologyTumor ProgressionBone Marrow EvaluationBone Marrow PathologyHematologic MalignanciesMultiple MyelomaBone Marrow StagingClinical Survival RatesMultiple Myeloma Of BonePlasma AlbuminPrognostic Factors AnalysisPrognostic IndicesPrognostic Staging SystemsSurvival Rates
BACKGROUND: Previous studies found a range of prognostic factors but no consensus about the proper staging system for multiple myeloma has been achieved. This study explored the prognostic factors to find a staging system for multiple myeloma most suitable for Chinese patients. METHODS: Between February 1990 to August 2004, 206 patients (138 men and 68 women, mean aged (59 +/- 11) years) who were initially diagnosed as multiple myeloma in Changzheng Hospital (Shanghai, China) and had followup records were enrolled in this study. Potential prognostic factors were evaluated by univariate and multivariate analyses. Four staging systems were applied to compare their suitability for the patients. RESULTS: The median survival time of the patients was 33 months. The 1-, 3- and 5-year survival rates were 80.18%, 48.08% and 33.7% respectively. Factors identified as adversely affecting survival were older age, severe bone lesions, low haemoglobin, low platelet, low serum calcium, low serum albumin, high proportion of plasma cells in marrow, high serum creatinine, high serum beta(2) microglobulin and high C-reactive protein. Among these, only C-reactive protein, beta(2) microglobulin, albumin and age were the independent prognostic factors. There were statistically significant survival differences among the three groups in Durie Salmon staging system and Bataille staging system, but not in British Medical Research Council staging system or International Staging System. CONCLUSIONS: High beta(2) microglobulin, high C-reactive protein, low albumin and old age are independent prognostic factors of multiple myeloma. Bataille staging system appears to be optimal for Chinese multiple myeloma patients.
11
International Staging System for Multiple Myeloma
Philip R. Greipp, Jesús F. San Miguel, Brian G.M. Durie et al. · Journal of Clinical Oncology · 2005 · 2.9K citations
Medicine, Hematology, Oncology +14
C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system
Régis Bataille, Mario Boccadoro, Bernard Klein et al. · Blood · 1992 · 288 citations · Full text
Medicine, Immunology, Pathology +10
Targeting β2-microglobulin for induction of tumor apoptosis in human hematological malignancies
Jing Yang, Jianfei Qian, Michele Wezeman et al. · Cancer Cell · 2006 · 95 citations · Full text
Medicine, Hematology, Oncology +14